Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash from Operations: 2013-2025

Historic Cash from Operations for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to -$6.5 million.

  • Theravance Biopharma's Cash from Operations fell 25.25% to -$6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $243.7 million, marking a year-over-year increase of 2221.55%. This contributed to the annual value of -$11.5 million for FY2024, which is 57.27% up from last year.
  • Theravance Biopharma's Cash from Operations amounted to -$6.5 million in Q3 2025, which was down 103.13% from $208.1 million recorded in Q2 2025.
  • Theravance Biopharma's Cash from Operations' 5-year high stood at $208.1 million during Q2 2025, with a 5-year trough of -$124.1 million in Q4 2022.
  • Moreover, its 3-year median value for Cash from Operations was -$2.5 million (2023), whereas its average is $18.7 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first tumbled by 174.15% in 2022, then soared by 4,812.89% in 2025.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Cash from Operations stood at -$45.2 million in 2021, then plummeted by 174.15% to -$124.1 million in 2022, then skyrocketed by 99.31% to -$854,000 in 2023, then dropped by 5.62% to -$902,000 in 2024, then fell by 25.25% to -$6.5 million in 2025.
  • Its last three reported values are -$6.5 million in Q3 2025, $208.1 million for Q2 2025, and $43.0 million during Q1 2025.